Weekly Digest – March 2026 Weekly Digest – March 2026 23 March 2026: ENHERTU approved in Japan as first tumor agnostic HER2 directed medicine for previously treated patients with HER2 positive metastatic solid tumors Japan’s MHLW has approved ENHERTU for […]
Weekly Digest – March 2026 Weekly Digest – March 2026 23 March 2026: GSK’s B7-H3-targeted ADC, Risvutatug rezetecan, granted Orphan Drug Designation for small-cell lung cancer in Japan GSK’s investigational B7-H3-targeted ADC, risvutatug rezetecan (Ris-Rez), has received ODD in Japan […]
Weekly Digest – March 2026 Weekly Digest – March 2026 25 March 2026: Tempus announces strategic collaboration with Daiichi Sankyo to advance AI-driven biomarker discovery and clinical differentiation across an ADC clinical program Tempus has entered into a strategic collaboration […]
Weekly Digest – March 2026 Weekly Digest – March 2026 23 March 2026: GlycoNex Inc. and Nippon Kayaku Co., Ltd. enter collaboration to advance next-generation ADC candidate GNX201-ADC GlycoNex and Nippon Kayaku have entered into a strategic collaboration to advance […]
Weekly Digest – March 2026 Weekly Digest – March 2026 13 March 2026: Alphamab Oncology announces IND application for innovative EGFR/HER3 dual payload bispecific ADC JSKN021 was officially accepted by CDE Alphamab Oncology has achieved a key regulatory milestone, as […]
Weekly Digest – March 2026 Weekly Digest – March 2026 20 March 2026: Alphamab Oncology announces the first patient dosed in a Phase 3 clinical study for triple-negative breast cancer of TROP2/HER3 bispecific ADC JSKN016 Alphamab Oncology has reached a […]
Weekly Digest – March 2026 Weekly Digest – March 2026 16 March 2026: CytomX’s Varsetatug Masetecan continues to demonstrate positive data supporting potential as a new treatment option in late-line colorectal cancer CytomX Therapeutics has strengthened its position in next-generation […]
Weekly Digest – March 2026 Weekly Digest – March 2026 17 March 2026: Alphamab Oncology announces the first patient dosed in a Phase 1 clinical study of PD-L1/VEGFR2 bispecific ADC JSKN027 Alphamab Oncology continues to expand its ADC pipeline, announcing […]
Weekly Digest – March 2026 Weekly Digest – March 2026 17 March 2026: Voro Therapeutics announced research collaboration with Daiichi Sankyo to advance PrimeBody™ technology for next-generation tumor-activated ADCs Voro Therapeutics has entered a strategic research collaboration with Daiichi Sankyo, […]
Weekly Digest – March 2026 Weekly Digest – March 2026 18 March 2026: Aptamer Group initiated Optimer radiopharmaceutical programme with Radiopharmium Ltd Aptamer Group plc has officially entered the fast-growing radiopharmaceutical space, launching a targeted programme built around its Optimer […]
